Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1).
Hodgkin
hematology
lymphoma
neurology
neuropathy
Journal
Clinical case reports
ISSN: 2050-0904
Titre abrégé: Clin Case Rep
Pays: England
ID NLM: 101620385
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
07
05
2021
revised:
30
03
2022
accepted:
05
04
2022
entrez:
11
5
2022
pubmed:
12
5
2022
medline:
12
5
2022
Statut:
epublish
Résumé
Treatment for Hodgkin lymphoma (HL) in adults comprises substantial risk of chemotherapy-induced peripheral neurotoxicity. Here, we describe the case of patient with Charcot-Marie-Tooth disease or HSMN1 and advanced Hodgkin lymphoma undergoing treatment with modified BEACOPP achieving complete remission without major aggravation of neurological symptoms.
Identifiants
pubmed: 35540715
doi: 10.1002/ccr3.5766
pii: CCR35766
pmc: PMC9069391
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e05766Informations de copyright
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Br J Haematol. 2001 Nov;115(2):323-5
pubmed: 11703329
Gynecol Oncol. 2005 May;97(2):710-2
pubmed: 15863189
J Neurosci. 2014 Nov 26;34(48):16140-52
pubmed: 25429154
J Peripher Nerv Syst. 2007 Jun;12(2):139-41
pubmed: 17565539
JAMA. 1985 Jul 26;254(4):507
pubmed: 4009878
Clin Med Insights Oncol. 2018 Jan 31;12:1179554918754885
pubmed: 29434481
J Pediatr Hematol Oncol. 2012 Apr;34(3):239-41
pubmed: 22246157
Med Pediatr Oncol. 1996 Apr;26(4):280-3
pubmed: 8600343
Pharmacol Res. 2015 Jul;97:122-30
pubmed: 25959210
Pediatr Blood Cancer. 2008 Apr;50(4):874-6
pubmed: 17514737
Med Pediatr Oncol. 1995 Aug;25(2):113-6
pubmed: 7603395
Ann Med Interne (Paris). 1990;141(8):709-10
pubmed: 2091516
Clin Case Rep. 2022 May 05;10(5):e05766
pubmed: 35540715
Lancet. 2012 May 12;379(9828):1791-9
pubmed: 22480758
JAMA. 1984 Nov 23-30;252(20):2862-3
pubmed: 6092732
Rinsho Ketsueki. 1999 May;40(5):414-9
pubmed: 10390891
Ann Neurol. 2017 Jun;81(6):772-781
pubmed: 28486769
Acta Oncol. 2018 Mar;57(3):403-411
pubmed: 29243538
J Pediatr Hematol Oncol. 2003 Apr;25(4):316-20
pubmed: 12679647
N Engl J Med. 1972 Jun 22;286(25):1369-70
pubmed: 5027400
J Am Osteopath Assoc. 1999 Mar;99(3):165-7
pubmed: 10217912
J Am Podiatr Med Assoc. 2003 May-Jun;93(3):229-33
pubmed: 12756314
Lancet. 2018 Dec 23;390(10114):2790-2802
pubmed: 29061295
Med Pediatr Oncol. 2003 Jan;40(1):39-43
pubmed: 12426685
Pediatr Blood Cancer. 2009 Feb;52(2):298-300
pubmed: 18837430
J Pediatr Hematol Oncol. 2009 Oct;31(10):787-9
pubmed: 19770686
Mol Neurobiol. 2013 Apr;47(2):673-98
pubmed: 23224996
Pediatr Blood Cancer. 2004 Oct;43(5):606-9
pubmed: 15382281
Neurology. 2003 Jan 28;60(2):337-40
pubmed: 12552058
Med Pediatr Oncol. 1989;17(6):520-3
pubmed: 2685529
Pediatr Hematol Oncol. 1988;5(1):61-4
pubmed: 3152952
Brain. 1980 Jun;103(2):259-80
pubmed: 7397478
J Pediatr Hematol Oncol. 2008 Jul;30(7):519-21
pubmed: 18797198
Med J Aust. 1985 Sep 30;143(7):305-6
pubmed: 4046919
Ann Oncol. 2000 Jun;11(6):743-7
pubmed: 10942065
BMJ Case Rep. 2017 Apr 24;2017:
pubmed: 28438772
J Neurol Neurosurg Psychiatry. 2012 Jul;83(7):706-10
pubmed: 22577229
Ann Oncol. 2001 Mar;12(3):422
pubmed: 11332159
Arch Dis Child. 1999 Nov;81(5):442-3
pubmed: 10519723
Cancer. 1996 Apr 1;77(7):1356-62
pubmed: 8608515
Neurogenetics. 2012 Feb;13(1):77-82
pubmed: 22271166
Appl Clin Genet. 2015 Oct 19;8:235-43
pubmed: 26527893